RxDoctor Payments Data

R Richard Sloop, MD

Neurology · Yakima, WANPI 1548365521

Payments from drug & device makers

$1,553in general payments, 2019–2025

Across 5 payments — averaging $310.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$33
$108,080in research payments, 2019–2025

Across 1 payment — averaging $108,080 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$108K

What the payments were for

  • Food & beverage$1329%
  • Education$3371%

General payments by program year

20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie3$1,520
UCB, Inc.2$33

How this compares

$1,553 in reported general payments places this provider in the 65th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$128,173
Medicare patients
351
Services billed
5,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab11$108,500
IngrezzaValbenazine Tosylate14$104,713
Carbidopa-LevodopaCarbidopa/Levodopa597$35,452
Dalfampridine ErDalfampridine11$21,042
Glatiramer Acetate11$17,783
Entacapone27$9,817
NayzilamMidazolam12$7,856
Levetiracetam144$7,763
Carbidopa-Levodopa ErCarbidopa/Levodopa80$4,670
Gabapentin150$4,013
AmantadineAmantadine Hcl65$3,672
Carbamazepine48$3,609
Pramipexole DihydrochloridePramipexole Di-Hcl135$3,600
Lamotrigine154$3,384
Divalproex Sodium46$3,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Nayzilam$33$7,85612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 418 neurology providers in Washington.

Other neurology in Yakima

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →